Scinovex
article Open AccessTop 1% cited

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

BMJ · 2021 · Vol. 373 · pp. n1088–n1088
Jamie Lopez BernalNick AndrewsCharlotte GowerChris RobertsonJulia StoweElise TessierRuth SimmonsSimon CottrellRichard J. RobertsMark G. O’DohertyKevin BrownClaire CameronDiane StocktonJim McMenaminMary Ramsay

Abstract

Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease. Both vaccines showed similar effects. Protection was maintained for the duration of follow-up (>6 weeks). A second dose of BNT162b2 was associated with further protection against symptomatic disease. A clear effect of the vaccines against the B.1.1.7 variant was found.

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studiesCoronavirus disease 2019 (COVID-19)Medicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PediatricsTest (biology)Family medicineVirologyInternal medicineOutbreak

MeSH terms

COVID-19SARS-CoV-2COVID-19 VaccinesCOVID-19 TestingBNT162 VaccineChAdOx1 nCoV-19AgedAged, 80 and overEnglandFemaleHospitalizationHumansMaleVaccinationCase-Control Studies

Funding

  • Public Health England
Citations
1,387
FWCI
85.37
field-weighted impact
References
26
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.